Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)
|
December 16, 2015
Single-Nucleotide Polymorphism to Associate Cancer Risk
Victoria Shaw, Katie Bullock, William Greenhalf
Neoplasia (New York, N.Y.)
|
June 26, 2026
The benefit of deep genomic testing for asymptomatic high-risk individuals undergoing surveillance for pancreatic adenocarcinoma: European registry for hereditary pancreatic diseases (EUROPAC-PLUS)
Phillip J Hopley, Annabelle Boughey, Katie Bullock, et al.
Scientific Reports
|
April 24, 2023
Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways
Leonard M Quinn, Sam Haldenby, Philip Antzcak, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 10, 2022
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Richard FitzGerald, Laura Dickinson, Laura Else, et al.
The Journal of Antimicrobial Chemotherapy
|
June 16, 2026
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection
Saye H Khoo, Richard FitzGerald, Christopher J Edwards, et al.
Clinical Pharmacology and Therapeutics
|
March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.
Nature Communications
|
November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
I'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
The Lancet. Infectious Diseases
|
October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Saye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
The Journal of Antimicrobial Chemotherapy
|
August 27, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Saye H Khoo, Richard Fitzgerald, Thomas Fletcher, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Methods in Molecular Biology (Clifton, N.J.)
|
December 16, 2015
Single-Nucleotide Polymorphism to Associate Cancer Risk
Victoria Shaw, Katie Bullock, William Greenhalf
Neoplasia (New York, N.Y.)
|
June 26, 2026
The benefit of deep genomic testing for asymptomatic high-risk individuals undergoing surveillance for pancreatic adenocarcinoma: European registry for hereditary pancreatic diseases (EUROPAC-PLUS)
Phillip J Hopley, Annabelle Boughey, Katie Bullock, et al.
Scientific Reports
|
April 24, 2023
Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways
Leonard M Quinn, Sam Haldenby, Philip Antzcak, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 10, 2022
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Richard FitzGerald, Laura Dickinson, Laura Else, et al.
The Journal of Antimicrobial Chemotherapy
|
June 16, 2026
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection
Saye H Khoo, Richard FitzGerald, Christopher J Edwards, et al.
Clinical Pharmacology and Therapeutics
|
March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.
Nature Communications
|
November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
I'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
The Lancet. Infectious Diseases
|
October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Saye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
The Journal of Antimicrobial Chemotherapy
|
August 27, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Saye H Khoo, Richard Fitzgerald, Thomas Fletcher, et al.
Page
of 1